劲方医药GFH375片启动Ib/II期临床 适应症为晚期实体瘤

新浪财经
Oct 11, 2025

药物临床试验登记与信息公示平台数据显示,劲方医药科技(上海)有限公司的一项多中心、开放标签,探索GFH375联合西妥昔单抗或AG在实体瘤参与者中的安全性/耐受性、PK特征,探索联合用药疗效的Ib/II期临床研究已启动。临床试验登记号为CTR20253996,首次公示信息日期为2025年10月11日。该药物剂型为片剂,规格为100mg/片,用法为口服,按方案规定使用。本次试验Ib期目的为评估...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10